Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)
Clinical trial NCT01685021 · TERMINATED
Trial details
- NCT number
- NCT01685021
- Sponsor
- MorphoSys AG
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-04-01
- Primary completion
- 2015-03-01
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.